S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
NASDAQ:CFMS

Conformis - CFMS Stock Forecast, Price & News

$2.62
+0.06 (+2.34%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.59
$2.80
50-Day Range
$2.31
$3.78
52-Week Range
$1.20
$18.77
Volume
44,218 shs
Average Volume
37,952 shs
Market Capitalization
$19.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

Conformis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
71.8% Upside
$4.50 Price Target
Short Interest
Healthy
0.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($8.32) to ($5.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

332nd out of 1,029 stocks

Surgical Appliances & Supplies Industry

9th out of 23 stocks

CFMS stock logo

About Conformis (NASDAQ:CFMS) Stock

ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States, Germany, and Rest of the World. The firm's products include iUni, iDuo, iTotal CR, and iTotal. The company was founded by Philipp Lang in 2004 and is headquartered in Billerica, MA.

Receive CFMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conformis and its competitors with MarketBeat's FREE daily newsletter.

CFMS Stock News Headlines

A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Conformis Announces Full Commercial Launch of Imprint™
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Conformis, Inc. Effects 1-for-25 Reverse Stock Split
Conformis Reports Third Quarter 2022 Financial Results
Conformis, Inc. (CFMS)
Here's Why ConforMIS (CFMS) Stock is Tanking Today
See More Headlines
Receive CFMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conformis and its competitors with MarketBeat's FREE daily newsletter.

CFMS Company Calendar

Last Earnings
11/03/2021
Today
2/04/2023
Next Earnings (Confirmed)
3/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CFMS
Employees
310
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.50
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+71.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-2,410,000.00
Net Margins
-104.46%
Pretax Margin
-104.45%

Debt

Sales & Book Value

Annual Sales
$99.86 million
Cash Flow
$0.26 per share
Book Value
$13.51 per share

Miscellaneous

Free Float
7,239,000
Market Cap
$19.70 million
Optionable
Not Optionable
Beta
1.03

Key Executives

  • Mark A. AugustiMark A. Augusti
    President, Chief Executive Officer & Director
  • Michael Fillion
    Chief Operating Officer
  • Robert S. HoweRobert S. Howe
    CFO, Treasurer & Principal Accounting Officer
  • John Slamin
    Chief Technology Officer
  • Marc Quartulli
    Vice President-Clinical Affairs & Market Access













CFMS Stock - Frequently Asked Questions

Should I buy or sell Conformis stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Conformis in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CFMS shares.
View CFMS analyst ratings
or view top-rated stocks.

What is Conformis' stock price forecast for 2023?

2 analysts have issued 12 month target prices for Conformis' stock. Their CFMS share price forecasts range from $1.00 to $8.00. On average, they predict the company's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 71.8% from the stock's current price.
View analysts price targets for CFMS
or view top-rated stocks among Wall Street analysts.

How have CFMS shares performed in 2023?

Conformis' stock was trading at $3.32 at the beginning of the year. Since then, CFMS stock has decreased by 21.1% and is now trading at $2.62.
View the best growth stocks for 2023 here
.

When is Conformis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023.
View our CFMS earnings forecast
.

How can I listen to Conformis' earnings call?

Conformis will be holding an earnings conference call on Wednesday, March 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Conformis' earnings last quarter?

Conformis, Inc. (NASDAQ:CFMS) issued its quarterly earnings data on Wednesday, November, 3rd. The medical instruments supplier reported ($0.07) EPS for the quarter, meeting analysts' consensus estimates of ($0.07). The medical instruments supplier earned $14.25 million during the quarter, compared to the consensus estimate of $14.08 million. Conformis had a negative net margin of 104.46% and a negative trailing twelve-month return on equity of 78.14%. During the same period in the previous year, the firm earned ($0.09) EPS.

What guidance has Conformis issued on next quarter's earnings?

Conformis issued an update on its fourth quarter 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $13.00 million-$14.00 million, compared to the consensus revenue estimate of $15.99 million.

What is Mark Augusti's approval rating as Conformis' CEO?

15 employees have rated Conformis Chief Executive Officer Mark Augusti on Glassdoor.com. Mark Augusti has an approval rating of 55% among the company's employees. This puts Mark Augusti in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Conformis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Conformis investors own include Advanced Micro Devices (AMD), Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Trevena (TRVN), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and AT&T (T).

When did Conformis IPO?

(CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What is Conformis' stock symbol?

Conformis trades on the NASDAQ under the ticker symbol "CFMS."

Who are Conformis' major shareholders?

Conformis' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include J Brent Alldredge, Kenneth P Fallon III, Mark A Augusti, Mark A Augusti and Robert S Howe.
View institutional ownership trends
.

How do I buy shares of Conformis?

Shares of CFMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Conformis' stock price today?

One share of CFMS stock can currently be purchased for approximately $2.62.

How much money does Conformis make?

Conformis (NASDAQ:CFMS) has a market capitalization of $19.70 million and generates $99.86 million in revenue each year. The medical instruments supplier earns $-2,410,000.00 in net income (profit) each year or ($8.75) on an earnings per share basis.

How many employees does Conformis have?

The company employs 310 workers across the globe.

How can I contact Conformis?

Conformis' mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The official website for the company is www.conformis.com. The medical instruments supplier can be reached via phone at (781) 345-9001, via email at ir@conformis.com, or via fax at 781-345-0147.

This page (NASDAQ:CFMS) was last updated on 2/4/2023 by MarketBeat.com Staff